Reference:USA Informed Consent - FDA Guidance for IRBs, Clinical Investigators, and Sponsors Aug-2023 V.: Difference between revisions
From GxPlex
Gxplex admin (talk | contribs) m 1 revision imported |
imported>GxPlexBot Import from GxPlex Excel |
||
| Line 4: | Line 4: | ||
|RefDocPart=V. | |RefDocPart=V. | ||
|RefLanguage=EN | |RefLanguage=EN | ||
| | |RefTags=TAG-00026-Min-isc ++ TAG-00112-Ass-nve ++ TAG-00028-Leg-ich ++ TAG-00201-Cli-eSt | ||
| | |RefModule=3 | ||
| | |RefUnit=3.1.4 | ||
}} | }} | ||
| Line 14: | Line 14: | ||
|- | |- | ||
! colspan="2" class="gplx-infobox-header" | Reference Details | ! colspan="2" class="gplx-infobox-header" | Reference Details | ||
|- | |||
! Module | |||
| Module 3 — Unit 3.1.4 | |||
|- | |- | ||
! Scope | ! Scope | ||
| Line 30: | Line 33: | ||
| | | | ||
|- | |- | ||
! Tags | ! Tags | ||
| | | [[Glossary:TAG-00026-Min-isc|Minor / Paediatric]], [[Glossary:TAG-00112-Ass-nve|Assent]], [[Glossary:TAG-00028-Leg-ich|Legal representative]], [[Glossary:TAG-00201-Cli-eSt|Clinical investigation]] | ||
|- | |||
| | |||
|- | |||
| | |||
|- | |- | ||
! Comment | ! Comment | ||
Revision as of 17:29, 15 July 2026
| Document information | |
|---|---|
| Reference | USA Informed Consent -
FDA Guidance for IRBs, Clinical Investigators, and Sponsors Aug-2023 |
| Validity area | USA |
| Scope(s) | G |
| Document name | Informed Consent -
FDA Guidance for IRBs, Clinical Investigators, and Sponsors |
| Version / Revision | Aug-2023 |
| Status | Current |
| Document type | Official recommendation |
| Language(s) | EN |
| Description | Informed Consent
Guidance for IRBs, Clinical Investigators, and Sponsors |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Module | Module 3 — Unit 3.1.4 |
| Scope | G |
| Document part | V. |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags | Minor / Paediatric, Assent, Legal representative, Clinical investigation |
| Comment | FAQs on enrolling children in clinical investigations |
Content
V. FREQUENTLY ASKED QUESTIONS […] 1. What are some considerations for enrolling a child into a clinical investigation? [...] 2. Are there any additional protections required when enrolling children who are wards of the state? [...] 3. What are some considerations for enrolling non-English speaking subjects? [...] 4. What process should be followed when it is expected that subjects who do not understand English will be enrolled? [...] 5. What process should be followed when the enrollment of subjects who do not understand English is not expected? [...] 6. What should be considered when enrolling subjects with low literacy and numeracy? [...] 7. What should be considered when enrolling subjects with physical or sensory disabilities? [...] 8. What should be considered when enrolling adult subjects with impaired consent capacity? [...] 9. Who can serve as a legally authorized representative (LAR) and what is their role? [...] 10. How can informed consent be obtained through electronic methods? [...] 11. Can a subject participate in more than one clinical investigation simultaneously? [...] 12. How should data be handled when an enrolled subject decides to withdraw from a trial? [...] 13. What steps should be taken to inform subjects when a study is suspended or terminated? [...] 14. Should subjects be informed of aggregate study results at the completion of a trial? [...] 15. Is informed consent required to review patient records? [...] 16. How should subjects be informed of new information that may affect their willingness to continue participation in the research? [...]
